US Patents Granted for ARIUS Antibodies



    ARIUS' "target on the target" protected

    TSX: ARI

    TORONTO, March 8 /CNW/ - ARIUS Research Inc. (TSX: ARI) announced today
that it has been granted two new United States patents for antibodies within
their CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS'
partnered program for melanoma, breast and prostate cancers and protects the
valuable site on the disease target that the drug candidate binds to. The
Company's FunctionFIRST(TM) platform uses a unique process to discover
antibody drugs by identifying those that destroy cancer cells while leaving
normal cells alone. In the process the antibodies can attach themselves to the
cancer cell but they must hit the appropriate spot on the cell i.e. the
"target on the target", in order to destroy it. ARIUS' patent strategy has
successfully captured the discovery process, the antibody drug molecules and
now the spot on the target that is key to causing the cancer cell's
destruction.
    Patent 7,186,808 covers a second antibody within this program that kills
breast and prostate cancer cells. The patent also covers the use of the
antibody as a treatment for breast cancer.
    ARIUS has over 120 patents pending that will continue to enhance the
value of the company.
    "This patent provides additional commercial and scientific validation to
our drug discovery platform," said Dr. David Young, President and CEO of
ARIUS. "Our unique approach allows us to extract new value from a wide range
of cancer targets while identifying drug candidates that can be developed to
help patients."

    ARIUS Research Inc. is a biotechnology company dedicated to the discovery
and development of novel anticancer monoclonal antibodies (MAbs) focused on
destroying cancer cells. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs
targeting a variety of cancer indications. This antibody generation engine has
enabled ARIUS to assemble a growing pipeline, which is used for commercial
collaborations and in-house development. ARIUS has ongoing partnerships with
key biotechnology and drug development companies. The company is listed on the
TSX under the symbol "ARI".

    Forward-Looking Statement
    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    %SEDAR: 00013708E




For further information:

For further information: visit www.ariusresearch.com or contact Helen
Findlay, Executive Vice President, Telephone: (416) 862-2323 ext. 223, E-mail:
contact@ariusresearch.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890